INmune Bio Expands MSC Platform Collaboration with Anthony Nolan to Target Rare, Oncology, and Inflammatory Diseases

Event summary

  • INmune Bio and Anthony Nolan amended their Material Transfer and License Agreement on April 29, 2026, expanding their CORDStrom™ MSC platform collaboration.
  • The partnership focuses on developing treatments for Recessive Dystrophic Epidermolysis Bullosa (RDEB), oncology, and inflammatory diseases like Osteoarthritis and SLE.
  • CORDStrom™ leverages umbilical cord-derived MSCs, standardized through Anthony Nolan’s procurement and screening infrastructure, to ensure regulatory compliance and consistency.
  • The agreement includes rigorous GMP and HTA standards for traceability and quality management.

The big picture

This expanded collaboration addresses a long-standing challenge in MSC therapy: donor variability and manufacturing inconsistency. By standardizing umbilical cord-derived MSCs, INmune Bio aims to deliver scalable, 'off-the-shelf' cellular therapies. The partnership aligns with broader industry trends toward precision medicine and regulatory harmonization, particularly in rare and inflammatory diseases.

What we're watching

Regulatory Approval
The pace at which CORDStrom™ gains approval from the FDA, EMA, and MHRA will determine its commercial viability.
Clinical Success
Whether INmune Bio can demonstrate consistent efficacy across RDEB, oncology, and inflammatory disease indications.
Market Expansion
How the collaboration scales to meet global demand while maintaining high-quality standards.

Related topics

Biotechnology